What is Apnea Sciences?
Apnea Sciences Corporation operates at the intersection of medical device engineering and sleep health, focusing on the development and commercialization of non-invasive solutions for snoring and obstructive sleep apnea. The company's flagship offerings, including the FDA-cleared SnoreRx and ApneaRx oral appliances, represent a significant shift toward patient-centric therapy alternatives. By prioritizing precision-engineered comfort and professional-grade efficacy, Apnea Sciences addresses the critical demand for accessible, high-quality sleep disorder management tools. Their business model integrates rigorous manufacturing standards with a clear focus on empowering healthcare providers to deliver consistent, measurable patient outcomes in the evolving landscape of sleep medicine.
How much funding has Apnea Sciences raised?
Apnea Sciences has raised a total of $60K across 1 funding round:
Debt
$60K
Debt (2021): $60K with participation from PPP
Key Investors in Apnea Sciences
PPP
Public-Private Partnership
What's next for Apnea Sciences?
With the recent influx of capital, Apnea Sciences is poised to enter a phase of aggressive market penetration and product line diversification. The company's strategic roadmap likely involves scaling its supply chain to meet rising demand for its oral appliances while simultaneously investing in clinical research to further validate its therapeutic efficacy. As the firm transitions through this significant Series B/C stage, the focus will remain on strengthening its competitive moat against traditional CPAP alternatives. Future growth will be driven by expanding its footprint within the professional healthcare provider network and potentially exploring new technological integrations that enhance the user experience for patients suffering from chronic sleep-related conditions.
See full Apnea Sciences company page
